U.S., May 9 -- ClinicalTrials.gov registry received information related to the study (NCT07574684) titled 'Clinical Effects of Alpha-Lipoic Acid in Advanced NSCLC' on April 05.
Brief Summary: Non-small cell lung cancer (NSCLC) is a common and aggressive type of lung cancer often diagnosed at advanced stages, with limited treatment options and poor prognosis. Oxidative stress, inflammation, and dysregulated signaling pathways contribute to tumor progression, metastasis, and chemotherapy resistance. Alpha-lipoic acid (ALA), a potent antioxidant with anti-inflammatory properties, has shown promise in preclinical and early clinical studies by reducing oxidative stress, enhancing chemotherapy efficacy, and improving immune response. The aim of ...